Impact of Trimetazidine Treatment on 5-year Clinical Outcomes in Patients with Significant Coronary Artery Spasm: A Propensity Score Matching Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yong Hoon | - |
dc.contributor.author | Her, Ae-Young | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Choi, Byoung Geol | - |
dc.contributor.author | Choi, Se Yeon | - |
dc.contributor.author | Byun, Jae Kyeong | - |
dc.contributor.author | Mashaly, Ahmed | - |
dc.contributor.author | Park, Yoonjee | - |
dc.contributor.author | Jang, Won Young | - |
dc.contributor.author | Kim, Woohyeun | - |
dc.contributor.author | Choi, Jah Yeon | - |
dc.contributor.author | Park, Eun Jin | - |
dc.contributor.author | Na, Jin Oh | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.contributor.author | Lim, Hong Euy | - |
dc.contributor.author | Kim, Eung Ju | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.contributor.author | Seo, Hong Seog | - |
dc.contributor.author | Oh, Dong Joo | - |
dc.date.accessioned | 2021-09-02T13:34:23Z | - |
dc.date.available | 2021-09-02T13:34:23Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-04 | - |
dc.identifier.issn | 1175-3277 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/76644 | - |
dc.description.abstract | Objective We aimed to evaluate the additive benefit of trimetazidine with well-known antispasmodic agents such as calcium channel blockers and nitrate in patients with significant coronary artery spasm (CAS) as assessed by acetylcholine provocation test up to 5 years. Methods A total 1727 patients with significant CAS were enrolled. They were divided into two groups: a trimetazidine group (trimetazidine, diltiazem, and nitrate, n = 695), and control group (diltiazem and nitrate, n = 473). After propensity score matching analysis, two matched groups (441 pairs, n = 882, C-statistic = 0.673) were generated. The individual and composite clinical end points [mortality, myocardial infarction (MI), revascularization, cerebrovascular accident (CVA), major adverse cardiac events (MACE), major adverse cardiac or cerebrovascular events (MACCE), and recurrent angina] were assessed up to 5 years for the two groups. Results At 5 years, there were similar incidences of individual and composite hard endpoints including mortality, MI, revascularization, CVA, MACE, MACCE, and recurrent angina in the two groups. Conclusions Additional long-term (5-year) treatment with trimetazidine in combination with diltiazem and nitrate in patients with significant CAS was not associated with improved clinical outcomes compared with combination therapy with diltiazem and nitrate only (without trimetazidine). | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ADIS INT LTD | - |
dc.subject | VARIANT ANGINA | - |
dc.subject | VASCULAR ENDOTHELIUM | - |
dc.subject | VASOSPASTIC ANGINA | - |
dc.subject | PROGENITOR CELLS | - |
dc.subject | DISEASE | - |
dc.subject | ACETYLCHOLINE | - |
dc.subject | PATHOGENESIS | - |
dc.subject | STIMULATION | - |
dc.subject | MECHANISMS | - |
dc.subject | OXIDATION | - |
dc.title | Impact of Trimetazidine Treatment on 5-year Clinical Outcomes in Patients with Significant Coronary Artery Spasm: A Propensity Score Matching Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.contributor.affiliatedAuthor | Na, Jin Oh | - |
dc.contributor.affiliatedAuthor | Choi, Cheol Ung | - |
dc.contributor.affiliatedAuthor | Lim, Hong Euy | - |
dc.contributor.affiliatedAuthor | Kim, Eung Ju | - |
dc.contributor.affiliatedAuthor | Park, Chang Gyu | - |
dc.contributor.affiliatedAuthor | Seo, Hong Seog | - |
dc.contributor.affiliatedAuthor | Oh, Dong Joo | - |
dc.identifier.doi | 10.1007/s40256-017-0254-z | - |
dc.identifier.scopusid | 2-s2.0-85034065977 | - |
dc.identifier.wosid | 000427604800006 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, v.18, no.2, pp.117 - 127 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | - |
dc.citation.title | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | - |
dc.citation.volume | 18 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 117 | - |
dc.citation.endPage | 127 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | VARIANT ANGINA | - |
dc.subject.keywordPlus | VASCULAR ENDOTHELIUM | - |
dc.subject.keywordPlus | VASOSPASTIC ANGINA | - |
dc.subject.keywordPlus | PROGENITOR CELLS | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | ACETYLCHOLINE | - |
dc.subject.keywordPlus | PATHOGENESIS | - |
dc.subject.keywordPlus | STIMULATION | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | OXIDATION | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.